FDA swats away Supernus’ Parkinson’s disease infusion pump for 3rd time

The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump.

After two prior attempts to win FDA approval for its apomorphine infusion device for the continuous treatment of motor fluctuations (or “off” episodes) in Parkinson’s disease patients, the agency has once again rejected the therapy.